autologous bone marrow transplantation


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.
Related to autologous bone marrow transplantation: Hematopoietic stem cell transplantation

autologous bone marrow transplantation

A procedure in which haematopoietic stem cells are extracted (apheresed) from a patient with lymphoma and other cancers, who is treated with high-dose chemo- and/or radiotherapy to eliminate malignant cells in the bone marrow. The stem cells are then administered. ABMT is a standard second-line therapy for some lymphomas; it has a low risk of infection and has no risk of graft-versus-host disease, which is typical of allogeneic bone marrow transplantation. ABMT is less preferred for patients with acute myeloid leukaemia, in whom the relapse may occur as the patient’s marrow may contain malignant cells.

autologous bone marrow transplantation

Transplantation medicine The administration to an individual 'X' of his/her own BM, often to a leukemic Pt in relapse who, because a suitable HLA-matched donor is not available, would otherwise die of the disease. See Bone marrow.

autologous bone marrow transplantation

Abbreviation: ABMT
The harvesting and preservation of a patient's own blood-forming cells, followed by their eventual reintroduction into a patient. The procedure may be used to treat a variety of cancers and blood disorders. Current practice is to mobilize stem cells into the blood stream with growth factors and then to collect and filter the blood by leukapheresis. In leukapheresis stem cells are identified by a cell surface antigen called CD34. After desirable blood-forming cells with this antigen are removed from the patient's blood, high-dose chemotherapy, monoclonal antibody therapy, or radiation may be used to purge the marrow of diseased cells. Healthy CD34+ cells capable of rebuilding the bone marrow are then returned to the patient and stimulated to reproduce. Synonym: autologous hematopoietic stem cell transplantation
See also: transplantation
References in periodicals archive ?
Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.
Leukine is a yeast-derived granulocyte-macrophage colony stimulating factor, which is a white blood cell stimulant that has been shown to reduce infection, antibiotic use and hospital stays following autologous bone marrow transplantation in the treatment of certain cancers.
NEUPOGEN is currently marketed in the United States to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever and to reduce the duration of neutropenia following allogeneic and autologous bone marrow transplantation.
Leukine was first approved in 1991 for use to speed recovery of cancer patients undergoing autologous bone marrow transplantation and subsequently to improve survival of cancer patients whose bone marrow transplants have failed.
22, 1994, notifying CellPro that CellPro's first PMA application for its CEPRATE SC Stem Cell Concentration System, for autologous bone marrow transplantation, is not approvable without amendment to the application.
The data, of Phase I/II and Phase II trials in B-cell lymphoma patients who have undergone autologous bone marrow transplantation (ABMT), continue to show a substantial reduction in relapse rate as compared with that expected for ABMT patients.
A major problem in autologous bone marrow transplantation is protecting the normal cells from the effects of chemotherapeutic agents used to kill tumor cells.
The bone marrow transplant team at Leon Berard is the largest center in Europe for autologous bone marrow transplantation.
NASDAQ: CPRO) today announced that it has completed patient enrollment for the Phase III licensing trial of its CEPRATE(TM) SC Stem Cell Concentration System in autologous bone marrow transplantation to treat patients with breast cancer.
The trial established the drug's safety profile in patients with B-cell lymphoma who are in remission subsequent to autologous bone marrow transplantation (ABMT).
In a subset of patients in the early stage of chronic myelogenous leukemia (CML), autologous bone marrow transplantation utilizing Philadelphia chromosome-negative stem cells is well-tolerated and can result in prolonged recovery, Italian researchers claim.
One of the limitations of autologous bone marrow transplantations is the high relapse rate associated with this treatment.

Full browser ?